A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. This story was originally published on BioPharma Dive. To ...

Eli Lilly (NYSE:LLY) announced on Wednesday that its FDA-approved antitumor agent Verzenio, as part of a combination regimen, improved overall survival in a late-stage trial for certain patients with ...

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...

In the heat of the CDK4/6 market showdown, Eli Lilly has notched an overall survival win to back Verzenio’s case against Novartis’ rival offering. Lilly’s Verzenio has proven its ability to prolong ...

Pharmaceutical advancements continue to reshape the landscape of cancer treatment, offering new hope for patients and altering market dynamics. Recent developments in innovative therapies demonstrate ...

As monotherapy, imlunestrant significantly reduced the risk of progression or death by 38% compared to standard endocrine therapy (ET) in patients with ESR1 mutations As combination therapy, ...